|

Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies

RECRUITINGSponsored by Oslo University Hospital
Actively Recruiting
SponsorOslo University Hospital
Started2009-09
Est. completion2022-08
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02073500

Summary

The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* age \> 18 years
* confirmed diagnosis of peritoneal surface malignancy
* candidate for CRS-HIPEC
* written informed consent

Exclusion Criteria:

* none

Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.

Conditions5

CancerColorectal CarcinomaMesotheliomaOvarian CarcinomaPseudomyxoma Peritonei

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.